Reduced fixed dose tocilizumab 400 mg IV compared to weight-based dosing in critically ill patients with COVID-19: A before-after cohort study

BACKGROUND: Interleukin-6 inhibitors reduce mortality in severe COVID-19. British Columbia began using tocilizumab 8 mg/kg (maximum 800 mg) in January 2021 in critically ill patients with COVID-19, but due to drug shortages, decreased dosing to 400 mg IV fixed dose in April 2021. The aims of this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Stukas, Sophie, Goshua, George, Kinkade, Angus, Grey, Rebecca, Mah, Gregory, Biggs, Catherine M., Jamal, Shahin, Thiara, Sonny, Lau, Tim T.Y., Piszczek, Jolanta, Partovi, Nilu, Sweet, David D, Lee, Agnes Y.Y., Wellington, Cheryl L., Sekhon, Mypinder S., Chen, Luke Y.C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941850/
https://www.ncbi.nlm.nih.gov/pubmed/35345649
http://dx.doi.org/10.1016/j.lana.2022.100228

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941850/
https://www.ncbi.nlm.nih.gov/pubmed/35345649
http://dx.doi.org/10.1016/j.lana.2022.100228

Ejemplares similares